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Purpose. To investigate the inﬂuence of inﬂammatory molecules in the aqueous humour and on the ocular surface on the outcome
of glaucoma surgery. Methods. Thirty patients who needed antiglaucomatous surgery were included. The interleukin- (IL-) 8,
IL-1β, IL-6, IL-10, tumour necrosis factor- (TNF-) α; and IL-12 were determined from aqueous humour preoperatively and the
imprints of conjunctiva were analysed for expression of human leukocyte antigen- (HLA-)-DR after surgery by ﬂow cytometry.
The success of trabeculectomy was deﬁned as intraocular pressure less than 21 mmHg without antiglaucoma medication. Results.
Eyes with trabeculectomy failure at 3 months showed signiﬁcantly higher TNF-α and IL-6 levels in the aqueous than eyes with
successful surgery. Increased expression of HLA-DR on epithelial cells and antigen-presenting cells was not associated with the
trabeculectomy outcome. Conclusions. Higher preoperative levels of TNF-α and IL-6 in aqueous humour may contribute to the
development of inﬂammatory milieu and were associated with worse outcome of glaucoma surgery.
1.Introduction
Trabeculectomy is commonly performed in patients with
uncontrolled glaucoma and with the use of antimetabolites
and surgical technique modiﬁcation is successful in the
majority of patients [1]. The main reason for failure is
episcleralﬁbrosisandthickeningoftheconjunctivaoverlying
the area of ﬁltration. The inﬂammation and subsequent
scarring are intense in the early postoperative period, in
which most of the failures occur. The process of wound
healing and tissue remodelling continues indeﬁnitely after
surgery and results in increasing failure rate with longer
follow-up [2]. Risk factors which may inﬂuence the outcome
ofsurgeryinclude-previoussurgery,long-termuseoftopical
antiglaucoma medications, ocular inﬂammation, young age,
ethnic origin, and postoperative suture lysis [2–4].
To understand the mechanism of ﬁltering surgery failure
the research has mainly focused on conjunctiva. Changes
in the number of conjunctival ﬁbroblasts and inﬂammatory
cells were associated with increased risk of trabeculectomy
failure. Long-term use of antiglaucoma drops with preser-
vative benzalkonium chloride (BAK) induces subclinical
inﬂammation of conjunctiva with over expression of human
leukocyte antigen- (HLA-) DR on epithelial cells. Several
cytokines were found to stimulate proliferation of Tenon’s
capsule ﬁbroblasts, cells with a key role in scarring process,
such as TGF-β, TNF, and IL-1 [5, 6]. In trabeculectomy, a ﬁs-
tula drains aqueous humour from the anterior chamber into
the subconjunctival space. Also changes in the composition
of this aqueous could inﬂuence the scarring process [7, 8].
In the prospective study we examined the eﬀect of
ﬁve cytokines in the aqueous humour on the outcome of
trabeculectomy. We also investigated the superior bulbar
conjunctiva overlying the area of ﬁltration area for the
expression of HLA-DR,the markers of subclinical inﬂamma-
tion, on conjunctival epithelial cells and CD80 positive cells
(antigen-presenting cells) during follow-up to determine
whether changes in the expression of these molecules are
associated with the outcome of surgery.
2. Patients andMethods
Thirty patients (30 eyes) with uncontrolled intraocular
pressure on maximal topical antiglaucoma medication who2 Mediators of Inﬂammation
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Figure 1: Box plot of expression of HLA-DR on conjunctival
epithelial cells (MFI-mean ﬂuorescence intensity) collected by
impression cytology 1 month after surgery in eyes with surgical
success and failure at 6 months (P = .036). The boundaries of each
box indicate the 25th and 75th percentiles, the whiskers indicate
the minimum and maximum values, and the line within each box
indicates the median.
needed glaucoma surgery were included in this prospective
study. The study protocol was approved by National Ethics
Committee and all patients after receiving complete infor-
mation signed informed consent form for inclusion in the
study.
At the beginning of surgery after local anaesthesia
aqueous humour was obtained through the side incision
made by 15
◦ knife, avoiding any contact with limbal vessels
and iris. Aqueous humour (0.05–0.1mL) was drawn into a
conventional tuberculin syringe and samples were stored at
−70
◦C, until tested. Trabeculectomies were performed by a
fornix-based conjunctival access and a scleral ﬂap of 4 ×
3mm. In all patients mitomycin C (0.3mg/mL) was topically
applied for 3 minutes on a sponge beneath the conjunctiva.
The sclerectomy was made by Kelly’s punch using 2–3bites
to create an opening. Scleral ﬂap was closed with 2-4 sutures,
of those 1-2 releasable. At the end of surgery, steroid and
antibiotic injections were given inferiorly. Topical steroids
and antibiotics were prescribed, and after 1 month only
steroid eye drops were instilled and stopped 3 months after
surgery.
Patients were scheduled for control visits 1 week, 1
month, 2, 3, 6, and 12 months after surgery, and more often
if deemed necessary.
The collection of conjunctival cells was performed by
the imprinting of the ocular surface onto Millipore ﬁlter
paper (VS 0.22μm pore size) after topical anaesthesia with
1-2 drops of oxybupropacaine [9]. Strips of ﬁlter paper
approximately 3 × 6mm were pressed ﬁrmly with a glass
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Figure 2: The expression of HLA-DR on conjunctival epithelial
cells (MFI-mean ﬂuorescence intensity) collected by impression
cytology 3 months after surgery in eyes with surgical success and
failure at 6 months of follow-up (P = .082). Open circles and
asterisk indicate the outliers.
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Figure 3: Aqueous levels of IL-6 in eyes with surgical success and
failure 3 months after surgery (P = .031). Asterisks indicate the
outliers.
rod on the ocular surface for 5 seconds and peeled oﬀ with a
forcepsandputinto1mLofphosphatebuﬀeredsaline.Three
imprints were collected from superior bulbar conjunctiva 1
month and 3 months after surgery.
Surgical success was deﬁned as intraocular pressure
(IOP)lessthan21mmHgwithoutantiglaucomamedicationMediators of Inﬂammation 3
Table 1: Median levels of cytokines (ranges) in the aqueous humour of 30 eyes (30 patients) and with respect to the type of glaucoma.
Cytokines (pg/mL) All eyes (N = 30 eyes) POAG (N = 26 eyes) EXG (N = 4e y e s ) P
IL-8 36 (19–177) 41 (19–177) 33 (28–53) .76
IL-1β 22 (15–48) 21 (15–48) 22 (18–27) .74
IL-6 27 (9–809) 38 (9–809) 15 (14–96) .16
IL-10 10 (3–19) 10 (3–19) 10 (9–12) .80
TNF-α 9 (4–21) 9 (4–21) 8 (6–9) .07
IL-12p70 14 (6–39) 14 (10–39) 12 (6–15) .05
Mann-Whitney U test; signiﬁcant at P< . 05.
POAG: primary open-angle glaucoma.
EXG: exfoliative glaucoma.
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Figure 4: Aqueous levels of TNF-α in eyes with surgical success and
failure 3 months after surgery (P = .025).
and was evaluated at month 3, 6, and month 12 follow-up
visits.
2.1. Flow Cytometry
2.1.1. Analysis of Cytokines in the Aqueous Humour. AB D
Human Inﬂammation CBA (Cytometric Bead Array) Kit
was used to quantitate IL-8, IL-1β, IL-6, IL-10, and TNF-
α and IL-12p70 protein levels in aqueous humour samples
(BD Bioscience Pharmingen San Diego, CA, USA). Sample
processing and data analysis were performed according to
the manufacturer’s instructions. Brieﬂy, aqueous humour
samples were incubated for 3 hours, light protected at
room temperature with the six cytokine capture beads
and PE-conjugated detection antibodies. After incubation
samples were washed and sample data were acquired using
a FACSCanto ﬂow cytometer (BD Bioscience, San Diego
CD, USA). Sample results were generated using graphical
and tabular format using the BD FCAP array software (BD
Bioscience, San Diego, CA, USA).
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Figure 5: Box plot of expression of HLA-DR on conjunctival
epithelial cells 1 month and 3 months after surgery in eyes with
successful and failed trabeculectomy (P = .001).
2.1.2. Analysis of Ocular Surface Imprints. Monoclonal anti-
bodies conjugated with ﬂuorochromes, CD80 (FITC), Anti-
Cytokeratin (FITC) and Anti-HLA-DR (PE), were purchased
fromBDPharmingen(SanJose,CA,USA).Atwo-parameter
analysis was performed to determine the expression of
HLA-DR on cytokeratin positive cells (epithelial cells) and
on CD80 positive cells (antigen-presenting cells). Flow
cytometric analysis was performed using BD FACSCanto
cytometer. At least 3000 events were collected per sample.
Cells were analyzed with BD FACSDiva software. The FACS
data are reported as mean ﬂuorescence intensities (MFI) and
as percentages of positive cells.
2.2. Statistical Analysis. For statistical analysis SPSS 15.0
software for Windows was used. Because the data were not4 Mediators of Inﬂammation
Table 2: Percentage of HLA-DR positive epithelial and CD80 positive cells (antigen-presenting cells) and mean ﬂuorescence intensity (MFI)
of ocular surface inﬂammatory molecules obtained by impression cytology at month 1 and 3 of follow-up in eyes with successful and failed
surgery.
%o fH L A - D Rp o s i t i v ec e l l s
and their MFI median values
(minimum-maximum)
3 months after surgery 6 months and 12 months after surgery
Success (n = 23) Failure (n = 7) P Success (n = 21) Failure (n = 9) P
%o fH L A - D Rp o s i t i v e
epithelial cells at month 1 52 (11–97) 83 (65–83) .058 58 (11–97) 52 (32–83) .960
MFI of HLA-DR on epithelial
cells at month 1
14834
(2742–55237)
16444
(3019–34050) .906 21369
(2742–55237) 8094 (3019–16444) .036
%o fH L A - D Rp o s i t i v eC D 8 0
cells at 1 month 64.5 (26–97) 82 (70–96) .128 65 (26–97) 68 (44–85) .926
MFI of HLA-DR on CD80
positive cells at 1 month 2686 (592–23661) 2082 (1861–22194) .844 2728 (592–23661) 2114 (1459–11540) .514
%o fH L A - D Rp o s i t i v e
epithelial cells at month 3 56 (7–93) 56 (30–84) .762 55 (7–88) 69 (30–93) .402
MFI of HLA-DR on epithelial
cells at month 3 5178 (533–20735) 3450 (835–8747) .493 6150 (533-20735) 2885 (1835–18634) .082
%o fH L A - D Rp o s i t i v eC D 8 0
cells at 3 month 67 (48–99) 67 (43–82) .401 66 (48-83) 73 (43–99) .920
MFI of HLA-DR on CD80
positive cells at 3 month 4456 (1028–17943) 6106 (1445–17808) .595 6050 (1028–17943) 2755 (1340–17808) .188
Mann-Whitney U test; signiﬁcant at P< . 05.
normally distributed, median, minimum, and maximum
values were calculated for the levels of cytokines and for the
expression of HLA-DR by epithelial and antigen-presenting
cells. Mann-Whitney U test was used to test the hypothesis
that there is no diﬀerence in the levels of cytokines and in
the expression of inﬂammatory markers between the eyes
with successful and failed surgery. The signiﬁcance of the
diﬀerence in the expression of HLA-DR on epithelial and
antigen-presenting cells 1 and 3 months after surgery was
tested with paired sample t-test. P values less than .05 were
considered signiﬁcant.
3. Results
Aqueous humour specimens from 30 patients undergoing
trabeculectomy (13 females, 17 males) with the mean age
63.6 years (standard deviation 10.3 years) were analyzed for
cytokines. The levels of cytokines in all patients as well as
the values regarding the type of glaucoma are summarized
in Table 1.
At 3 months of follow-up 23 eyes (patients) had suc-
cessful surgery (deﬁned as IOP less than 21mm Hg without
antiglaucoma medication), and at 6 and 12 months there
were 21 eyes with successful surgery. The median values and
ranges for the percentages of HLA-DR positive cytokeratin
cells (epithelial cells) and CD80 positive cells (antigen-
presentingcells),withtheirmedianﬂuorescenceintensityare
shown in Table 2. Mean ﬂuorescence intensity of HLA-DR
molecules on epithelial cells at 1 month and 3 months was
increased in eyes with successful surgery at 12 months, but
there was large scatter of the data (Figures 1 and 2).
Aqueous levels of cytokines in the eyes with surgical
success and failure are summarized in Table 3.W ef o u n d
signiﬁcantly higher levels of IL-6 and TNF-α in eyes with
surgical failure when compared to the eyes with surgical
success (Figures 3 and 4).
The expression of HLA-DR on epithelial cells was
signiﬁcantly lower 3 months compared to 1 month after
surgery (paired sample t-test; P = .001), both for the eyes
with surgical success and failure (Figure 5). There was no
signiﬁcant diﬀerence in the percentage of HLA-DR positive
epithelial and antigen-presenting cells as well as in the
expression of HLA-DR by antigen-presenting cells between
1 month and 3 months of follow-up (not shown).
4. Discussion
Several studies have investigated conjunctival biopsy spec-
imens from patients with glaucoma receiving long-term
antiglaucoma medication and after previous ocular surgery
before undergoing ﬁltration surgery. They have shown
increased number of conjunctival ﬁbroblasts and inﬂamma-
tory cells when compared to eyes without previous ocular
s u r g e r yo ro n l yb r i e ﬂ yt r e a t e d - p r i m a r ys u r g e r ye y e s[ 3,
10, 11]. Such preoperative subclinical inﬂammation was
identiﬁed as a risk factor for failure of trabeculectomy and
was attributed to the upregulation of the wound healing
response caused by an increase in the number and degree of
activation of these inﬂammatory cells [3, 10].
Conjunctival epithelium has been studied in impression
cytology specimens by ﬂow cytometry. In eyes treated over
long term without clinical inﬂammation, overexpression
of inﬂammatory marker HLA-DR and IL-6, IL-8, and IL-
10 was documented [11–13]. It was demonstrated that
the preservative benzalkonium chloride was the major
component in the eye drops responsible for toxic andMediators of Inﬂammation 5
Table 3: Concentration of cytokines in aqueous humour in patients with successful and failed surgery at 3, 6, and 12 months of follow-up.
Cytokines, median
(minimum-maximum)
(pg/mL)
3 months after surgery 6 months and 12 months after surgery
Success (n = 23) Failure (n = 7) P Success (n = 21) Failure (n = 9) P
IL-8 31 (19–177) 43 (29–70) .478 36 (11–177) 34 (28–137) .910
IL-1β 22 (15–48) 19 (17–41) .357 22 (15–48) 21(17–41) .504
IL-6 18 (9–809) 106 (26–375) .031 20 (9–809) 75 (15–629) .072
IL-10 10 (4–19) 11 (3–15) .983 11 (4–19) 9 (3–15) .341
TNF-α 9 (4–21) 10 (8–15) .025 9 (4–21) 10 (8–15) .101
IL-12p70 14 (6–39) 13 (11–24) .983 14 (6–39) 13 (12–24) .696
Mann-Whitney U test; signiﬁcant at P< . 05.
immunoinﬂammatory eﬀects or both in the conjunctiva
[11, 14].
In our study, we used impression cytology specimens
from the superior bulbar conjunctiva and ﬂow cytometry
to measure ocular surface inﬂammation 1 month and 3
months after trabeculectomy in an attempt to correlate
ocular surface changes with the outcome of surgery. There
was a trend of increased number of HLA-DR positive
conjunctivalepithelialcellscollectedonemonthaftersurgery
infailureswhencomparedtosuccessesat3-monthfollow-up
(Table 2). In contrast to others, higher expression of HLA-
DR on conjunctival epithelial cells and antigen-presenting
cells was not more common in failures [15]. Interestingly,
the expression of HLA-DR on epithelial cells at month 1
and 3 was higher in eyes with successful surgery than in
failures, suggesting smaller ocular surface inﬂammation in
failures (Figures 1 and 2). This cannot be explained by the
diﬀerence in postoperative treatment regimen between the
two groups, as all patients were receiving topical dexam-
ethasoneeyedrops(Maxidex,Alcon)containingpreservative
benzalkonium chloride for up to 3 months after surgery
that is, at the time points the specimens were collected. It
was demonstrated that eyes with good intraocular pressure
control have microcysts at the bleb surface containing aque-
ous humour, indicating a transcellular pathway of aqueous
[16, 17]. Hence, the diﬀerent expression of HLA-DR on
epithelial cells in eyes with such functioning blebs may be
also induced by the composition of aqueous.
Because the imprints of ocular surface were not collected
before surgery, it remains unknown whether there was any
diﬀerence in preoperative HLA-DR expression between the
eyes with successful and failed surgery. In both groups there
was a reduction of HLA-DR expression on epithelial cells
over time, indicating diminished postoperative inﬂamma-
tion with longer follow-up (Figure 5).
The aqueous humour is known to contain several
cytokines capable of aﬀecting ﬁbroblast activity [18, 19].
TGF-β has been implicated in several ocular scarring pro-
cesses including proliferative vitreoretinopathy, conjunctival
wound healing, especially that occurring after trabeculec-
tomy [20]. It has been shown to be the most potent stimula-
torofhumanTenon’sﬁbroblastactivity.Inaddition,aqueous
concentrationsofTGF-β2 areincreasedinglaucomatouseyes
[21]. In patients with exfoliative glaucoma previous argon
laser trabeculoplasty (ALT) increased the risk of scarring
becauseofincreasedaqueouslevelsofactivatedTGF-β2 com-
paredtopatientswithoutALT[8].Amonoclonalantibodyto
TGF-β2 was developed to prevent the progression of ﬁbrosis
in patients undergoing trabeculectomy, but in a randomized
multicentre study the subconjunctival application of the
anti TGF-β2-antibody was not diﬀerent from placebo in
preventing trabeculectomy failure [22].
In this study, we used ﬂow cytometry to measure
cytokines in the aqueous humour of patients undergoing
trabeculectomy to evaluate whether preoperative changes in
the level of cytokines could predict the outcome of surgery.
The proinﬂammatory cytokines IL-1β, IL-6, IL-8, IL-12 and
TNF-α, and IL-10, an anti-inﬂammatory cytokine, were
analyzed preoperatively. We found that higher preoperative
levels of TNF-α and IL-6 in the aqueous humour were
present in eyes with surgical failure at 3 months (Table 3,
Figures 3 and 4).
Tumour necrosis factor-α is synthesized by macrophages,
monocytes, neutrophils, natural killer cells, and T cells [23].
TNF-α together with TGF-β is a major proinﬂammatory
and proﬁbrogenic cytokine expressed by ocular surface
tissues. During the inﬂammatory process, it orchestrates
the initiation of further leukocyte inﬁltration via adhe-
sion molecule upregulation, dendrite cell maturation and
survival, macrophage activation, and driving Th1 T cell
responses in experimental autoimmune uveitis [24]. TNF-
α together with IL-1β and VEGF causes breakdown of
blood-retinal barrier in a murine model of experimen-
tal autoimmune uveitis [25]. Cunliﬀe at al. have shown
that TNF and IL-1 stimulated proliferation of Tenon’s
capsule ﬁbroblasts in tissue culture [6]. We propose that
higher levels of TNF-α in aqueous humour stimulate
monocyte/macrophage-chemoattractant protein-1 (MCP-
1) gene and protein expression which could lead to an
increase in the number of monocytes/macrophages from
the subconjunctival tissue surrounding the ﬁstula. These
cells by producing proinﬂammatory and proﬁbrogenic
cytokines (e.g., TNF-α and TGF-β) increase activation and
transformation of conjunctival ﬁbroblasts with accelerated
extracellular matrix deposition and consequently intense
scarring response. Additionally, increased levels of TNF-α in
the aqueous stimulate neovascularisation and contribute to
stronger wound healing response.6 Mediators of Inﬂammation
Interleukin-6 is a macrophage-derived cytokine but is
also thought to be produced by ocular parenchymal cells
[26]. It is generally considered to be a proinﬂammatory
cytokine. Readily induced by TNF-α,I F N - γ,a n dI L - 1 ,I L -
6p r o m o t e sd i ﬀerentiation of B cells to plasma cells and
induces synthesis of acute phase proteins, such as ﬁbrinogen
and C-reactive protein. Increased levels of IL-6 were found
in aqueous humour in a murine model of experimental
autoimmune uveitis demonstrating an increased local pro-
duction at disease onset [27]. Also, in aqueous humour of
patientswithneovascularglaucoma,increasedconcentration
of IL-6 correlated with the severity of iris neovascularisation
[28]. Patients included in our study had primary open-angle
and exfoliative glaucoma only. We suggest that higher levels
of IL-6 in aqueous bathing the subconjuctival space after
trabeculectomy may increase postoperative inﬂammation
and lead to more intense ﬁbrosis.
Both TNF-α and IL-6 have been found elevated in
aqueous humour of patients with idiopathic uveitis, Behcet’s
disease and Fuchs’ heterochromic cyclitis [26, 29, 30].
Patients with uveitic glaucoma have also increased risk for
excessive scarring after trabeculectomy surgery [31].
Interleukin-1β, IL-8, IL-10, and IL-12 were not found to
be the risk factors for trabeculectomy failure.
The limitation of our study is a small number of patients
included. Also, aqueous humour was collected at one time
point only, at the beginning of trabeculectomy, and we do
not know about the changes in cytokine levels during follow-
up, which could support our results. Other cytokines not
investigated in our study may inﬂuence the outcome of
surgery as well as interactions between diﬀerent cytokines,
which cannot be studied in vivo. However, the study was
prospective with a 12-month follow-up, a period where most
of the surgical failures occur and also studied ocular surface
at the site of surgery.
The increased percentage and expression of HLA-DR
on conjunctival epithelial cells and antigen-presenting cells
were not associated with surgical failure. In contrast to
other authors the expression of inﬂammatory marker HLA-
DR on epithelial cells was elevated in eyes with successful
trabeculectomy when compared to eyes with surgical failure
[13].
5. Conclusions
In our study, inﬂammation of superior bulbar conjunctiva
detected as overexpression of inﬂammatory molecules one
and three months after surgery was not associated with
subconjunctival ﬁbrosis. Lower levels of TNF-α and IL-6
in aqueous humour were associated with better surgical
outcome in patients undergoing trabeculectomy.
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